1. Home
  2. ALLO vs NCA Comparison

ALLO vs NCA Comparison

Compare ALLO & NCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • NCA
  • Stock Information
  • Founded
  • ALLO 2017
  • NCA 1987
  • Country
  • ALLO United States
  • NCA United States
  • Employees
  • ALLO N/A
  • NCA N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • NCA Investment Managers
  • Sector
  • ALLO Health Care
  • NCA Finance
  • Exchange
  • ALLO Nasdaq
  • NCA Nasdaq
  • Market Cap
  • ALLO 252.9M
  • NCA 300.3M
  • IPO Year
  • ALLO 2018
  • NCA N/A
  • Fundamental
  • Price
  • ALLO $1.27
  • NCA $9.22
  • Analyst Decision
  • ALLO Buy
  • NCA
  • Analyst Count
  • ALLO 11
  • NCA 0
  • Target Price
  • ALLO $8.67
  • NCA N/A
  • AVG Volume (30 Days)
  • ALLO 2.3M
  • NCA 59.6K
  • Earning Date
  • ALLO 11-06-2025
  • NCA 01-01-0001
  • Dividend Yield
  • ALLO N/A
  • NCA 3.92%
  • EPS Growth
  • ALLO N/A
  • NCA N/A
  • EPS
  • ALLO N/A
  • NCA N/A
  • Revenue
  • ALLO N/A
  • NCA N/A
  • Revenue This Year
  • ALLO N/A
  • NCA N/A
  • Revenue Next Year
  • ALLO $100.00
  • NCA N/A
  • P/E Ratio
  • ALLO N/A
  • NCA N/A
  • Revenue Growth
  • ALLO N/A
  • NCA N/A
  • 52 Week Low
  • ALLO $0.86
  • NCA $7.77
  • 52 Week High
  • ALLO $3.78
  • NCA $9.12
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 53.43
  • NCA 67.15
  • Support Level
  • ALLO $1.16
  • NCA $9.07
  • Resistance Level
  • ALLO $1.28
  • NCA $9.30
  • Average True Range (ATR)
  • ALLO 0.09
  • NCA 0.08
  • MACD
  • ALLO 0.01
  • NCA 0.00
  • Stochastic Oscillator
  • ALLO 70.68
  • NCA 68.57

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About NCA Nuveen California Municipal Value Fund

Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. Its primary objective is to provide current income exempt from regular federal and California income taxes. The fund's secondary objective is to enhance portfolio value relative to the California municipal bond market by investing in tax-exempt California municipal securities that the Fund's investment adviser and/or the Fund's sub-adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

Share on Social Networks: